LU101272B1 - Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding - Google Patents

Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding Download PDF

Info

Publication number
LU101272B1
LU101272B1 LU101272A LU101272A LU101272B1 LU 101272 B1 LU101272 B1 LU 101272B1 LU 101272 A LU101272 A LU 101272A LU 101272 A LU101272 A LU 101272A LU 101272 B1 LU101272 B1 LU 101272B1
Authority
LU
Luxembourg
Prior art keywords
composition
generating
tesla
composition according
silicon
Prior art date
Application number
LU101272A
Other languages
English (en)
Inventor
Christian Daniel Assoun
Original Assignee
Glycan Poland Sp Z O O
Glycan Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycan Poland Sp Z O O, Glycan Ind Llc filed Critical Glycan Poland Sp Z O O
Priority to LU101272A priority Critical patent/LU101272B1/en
Priority to IE20200056U priority patent/IE20200056U1/en
Priority to US16/906,450 priority patent/US20210000867A1/en
Application granted granted Critical
Publication of LU101272B1 publication Critical patent/LU101272B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (22)

-1- LU101272 REVENDICATIONS
1. Composition comprenant du zinc Zn-FLNT4 et du silicium SiHR57 sous la forme de (3(CH3Si(OH)3-R(COO x)) pour une utilisation comme un médicament ou en thérapie.
2. Composition selon la revendication 1, dans laquelle x est choisi dans le groupe comprenant sodium, potassium et lithium.
3. Composition selon la revendication 1 ou 2, dans laquelle Zn-FLNT4 est associé à une molécule de D-fructose.
4. Composition selon l’une quelconque des revendications 1 à 3, pour une utilisation dans un procédé pour le traitement de maladies neurodégénératives et cardiovasculaires.
5. Composition selon la revendication 4, où le procédé comprend en outre l’utilisation d’une troisième composition comprenant des cyclodextrines (xBy).
6. Composition selon la revendication 4 ou 5, où le procédé comprend en outre l’utilisation d’une quatrième composition comprenant de l’acide ursodésoxycholique.
7. Composition selon l’une quelconque des revendications 4 à 6, où le procédé comprend en outre l’utilisation de cellules souches primaires.
8. Composition selon l’une quelconque des revendications 1 à 7, pour une utilisation dans un procédé pour atténuer une neurodégénérescence associée à une exposition à au moins un élément choisi parmi des particules énergétiques solaires, des rayons cosmiques galactiques et une radiation extra-terrestre.
9. Composition selon la revendication 8, incorporée dans un ou plusieurs complément(s) alimentaire(s) pour l’homme en vue d’une administration.
10. Procédé pour aligner le spin de molécules dans la composition selon la revendication 1, comprenant les étapes consistant à: localiser au moins un conduit adjacent à une source d’ondes radio électromagnétiques (EM-RF); faire circuler la composition à travers le conduit; et générer une EM-RF avec la source, pour soumettre la composition dans le conduit à la EM-RF générée.
11. — Procédé selon la revendication 10, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF avec une intensité dans l’intervalle de 0,05 Tesla à 0,3 Tesla.
12. Procédé selon la revendication 10, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF avec une intensité dans l’intervalle de 1,5 Tesla à 3 Tesla.
-2- LU101272
13. Procédé selon la revendication 11 ou 12, dans laquelle l’étape de génération comprend en outre la génération de la EM-RF comme une EM-RF permanente, une EM- RF modulée par impulsion ou une EM-RF oscillante.
14. Procédé selon l’une quelconque des revendications 10 à 13, comprenant les étapes supplémentaires consistant à: administrer la composition soumise à une EM-RF au patient; localiser au moins une zone du patient incluant la composition administrée adjacente à un appareil d’imagerie par résonance magnétique (IRM); et générer une deuxième EM-RF avec l’appareil IRM, pour soumettre la zone incluant la composition administrée à la deuxième EM-RF générée.
15. Procédé selon la revendication 14, dans laquelle l’étape de génération de la deuxième EM-RF comprend en outre la génération de la deuxième EM-RF avec une intensité dans l’intervalle de 1,5 Tesla à 3 Tesla.
16. Procédé selon l’une quelconque des revendications 10 à 15, dans laquelle l’étape d’administration est effectuée par un moyen choisi parmi ingestion orale, pulvérisation endonasale ou \intranasale, sonde dermique, patch transdermique et injection intrapéritonéale ou intracrânienne.
17. Procédé selon l’une quelconque des revendications 10 à 16, dans laquelle le conduit est une partie d’une seringue à vitesse régulée.
18. Particule de cyclodextrine pour administrer la composition selon la revendication 1.
19. Particule de cyclodextrine selon la revendication 18, où la particule est façonnée comme une cage tridimensionnelle avec au moins une ouverture.
20. Particule de cyclodextrine selon la revendication 18 ou 19, où la particule est façonnée comme un tore.
21. Particule de cyclodextrine selon l’une quelconque des revendications 18 à 20, comprenant en outre des nanoparticules ou des picoparticules de silicium-germanium localisées sur une surface interne de la particule de cyclodextrine.
22. Particule de cyclodextrine selon l’une quelconque des revendications 18 à 21, comprenant en outre du carbonyle de zinc localisé sur une surface externe de la particule de cyclodextrine.
LU101272A 2019-06-19 2019-06-19 Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding LU101272B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
LU101272A LU101272B1 (en) 2019-06-19 2019-06-19 Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding
IE20200056U IE20200056U1 (en) 2019-06-19 2020-04-07 NEW ROUTE AND ENGINEERING PROTOCOLS FOR ALZHEIMER’s DISEASE PREVENTION, TREATMENT AND NEURONAL REBUILDING
US16/906,450 US20210000867A1 (en) 2019-06-19 2020-06-19 New route and engineering protocols for alzheimers disease prevention, treatment and neuronal rebuilding

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU101272A LU101272B1 (en) 2019-06-19 2019-06-19 Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding

Publications (1)

Publication Number Publication Date
LU101272B1 true LU101272B1 (en) 2020-12-28

Family

ID=67297235

Family Applications (1)

Application Number Title Priority Date Filing Date
LU101272A LU101272B1 (en) 2019-06-19 2019-06-19 Route and engineering protocols for alzheimer's disease prevention, treatment and neuronal rebuilding

Country Status (2)

Country Link
IE (1) IE20200056U1 (fr)
LU (1) LU101272B1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023089A1 (fr) 1993-07-23 1996-08-01 Jolinon Monique Procede de preparation de complexes organometalliques, les applications en tant que medicaments et en catalyses chimiques
WO2008055684A1 (fr) 2006-11-08 2008-05-15 Glycan-Pharma (Switzerland) Sa Procédé de traitement de déchets dangereux utilisant un plasma et dispositif de mise en œuvre du procédé
WO2008064888A1 (fr) 2006-11-30 2008-06-05 Glycan-Pharma Switzerland Sa Procédé de création d'énergie par traitement au plasma de métaux, de sels de métal et d'éléments chimiques non métalliques, et dispositif pour la mise en œuvre de ce procédé
US20180073361A1 (en) 2016-09-09 2018-03-15 Christian Daniel Assoun Plasmas for extraterrestrial resources and applied technologies (pert) space debris remediation, mining, and refining

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023089A1 (fr) 1993-07-23 1996-08-01 Jolinon Monique Procede de preparation de complexes organometalliques, les applications en tant que medicaments et en catalyses chimiques
WO2008055684A1 (fr) 2006-11-08 2008-05-15 Glycan-Pharma (Switzerland) Sa Procédé de traitement de déchets dangereux utilisant un plasma et dispositif de mise en œuvre du procédé
WO2008064888A1 (fr) 2006-11-30 2008-06-05 Glycan-Pharma Switzerland Sa Procédé de création d'énergie par traitement au plasma de métaux, de sels de métal et d'éléments chimiques non métalliques, et dispositif pour la mise en œuvre de ce procédé
US20180073361A1 (en) 2016-09-09 2018-03-15 Christian Daniel Assoun Plasmas for extraterrestrial resources and applied technologies (pert) space debris remediation, mining, and refining

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
AKASSOGLOU KAGALLIU DCHANG CJDAVALOS DGRUTZENDLER JHILLMAN EMCKHAKH BSKLEINFELD DMCGAVERN DBNELSON SJ: "Neurovascular and Immuno-Imaging: From Mechanisms to Therapies", PROCEEDINGS OF THE INAUGURAL SYMPOSIUM. FRONT NEUROSCI, vol. 10, 2016, pages 46
BLOOD FLOW METAB, vol. 31, 2011, pages 795 - 806
CARCINOGENESIS, vol. 31, no. 1, 29 October 2009 (2009-10-29), pages 59 - 70
CHEN BRKOZBERG MGBOUCHARD MBSHAIK MAHILLMAN EMC: "A critical role for the vascular endothelium in functional neurovascular coupling in the brain", JAHA, vol. 3, 2014, pages e000787
ELSEVIER CARBOHYDRATE RESEARCH, vol. 172, no. 1-15, January 1988 (1988-01-01), pages 1 - 10
GEESINKMEIJER, NEUROQUANTOLOGY, vol. 14, no. 1, March 2016 (2016-03-01), pages 106 - 125
HILLMAN EMC: "Out for Blood", SCIENTIFIC AMERICAN MIND, July 2014 (2014-07-01)
HILLMAN EMCAMOOZEGAR CBWANG TMCCASLIN AFHBOUCHARD MBMANSFIELD JRLEVENSON RM: "In-vivo optical imaging and dynamic contrast methods for biomedical research", PHIL. TRANS. ROYAL SOC A., vol. 369, no. 1955, 2011, pages 4620 - 4643
KOZBERG MCHEN BRBOUCHARD MBHILLMAN EMC: "Resolving the transition from negative to positive BOLD in the developing brain", PNAS, vol. 110, no. 11, 2013, pages 4380 - 5
LILI ZHANGXIANG ZOUBOHAN ZHANG, LIYUAN CUI, JIAYI ZHANGYING MAOLIANG CHENMINBIAO JI, LABEL-FREE IMAGING OF HEMOGLOBIN DEGRADATION AND HEMOSIDERIN FORMATION IN BRAIN TISSUES WITH FEMTOSECOND PUMP-PROBE MICROSCOPY
M. GRANDIC. ASSOUNR.A.CANUTOP. COURRIEREP.SOULAM.MAGIORRAA. LACIVITA: "Zn FLNT4", XVI INTERNATIONAL CANCER CONGRESS, 1994
M.GRANDIC.ASSOUNM.MAGGIORAG.NUMICOR.CANUTOP. COURRIERP.SOULA, ADVANCES IN MANAGEMENT OF MALIGNANCIES, 6 December 1993 (1993-12-06)
MA YSHAIK MAKIM SHKOZBERG MGTHIBODEAUX DNZHAO HTYU H.HILLMAN EMC: "Wide-field optical mapping of neural activity and brain haemodynamics: considerations and novel approaches", PHILOS TRANS R SOC LOND B BIOL SCI., vol. 371, 2016, pages 1705
MA YSHAIK MAKOZBERG MGKIM SHPORTES JPTIMERMAN DHILLMAN EMC: "Resting-state hemodynamics are spatiotemporally coupled to synchronized and symmetric neural activity in excitatory neurons", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. PNAS, vol. 113, no. 52, 2016, pages E8463 - E8471
MARCU LHILLMAN EMC: "In vivo Optical Imaging / Intravital Microscopy", J BIOPHOTONICS, vol. 10, no. 6-7, June 2017 (2017-06-01), pages 760 - 761
MCCASLIN AFHCHEN BRRADOSEVICH AJCAULI BHILLMAN EMCJ CEREB, IN-VIVO 3D MORPHOLOGY OF ASTROCYTE-VASCULATURE INTERACTIONS IN THE SOMATOSENSORY CORTEX: IMPLICATIONS FOR NEUROVASCULAR COUPLING
NIDHI SHRIVASTAVDEYU LIJOHN M. ESSIGMANN, CHEMICAL BIOLOGY OF MUTAGENESIS AND DNA REPAIR: CELLULAR RESPONSES TO DNA ALKYLATION, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.ov/pubmed/?term=Essimann%20JM%5BAuthor%5D&cauthor=true&cauthoruid=19875697LU>
No Search *
PROF. CHARLES L. LIMOLI: "Department of Radiation Oncology", 11 October 2017, UNIVERSITY OF CALIFORNIA IRVINE, MEDICAL SCIENCES I, article "Adenosine Kinase Inhibition Protects against Cranial Radiation-Induced Cognitive Dysfunction", pages: 92697 - 2695
QIU JBAIK ADLU LHILLMAN EMCZHUANG ZDONG CGUO XE: "Theoretical Analysis of Novel Quasi-3D Microscopy of Cell Deformation", CEL. MOL. BIOENG, vol. 5, no. 2, 2012, pages 165 - 172, XP035053270, DOI: doi:10.1007/s12195-011-0218-3
RAYSHUBSKIY AWOJTASIEWICZ TJMIKELL CBBOUCHARD MBTIMERMAN DYOUNGERMAN BEMCGOVERN RAOTTEN MLCANOLL, PDMCKHANN II GM: "Direct, intraoperative observation of -0. 1 Hz hemodynamic oscillations in awake human cortex: Implications for fMRf", NEUROLMAGE, vol. 87, 2014, pages 323 - 331, XP028817852, DOI: doi:10.1016/j.neuroimage.2013.10.044
RONERT WBRADFORD , DSC HENRY W.ALLEN THE ROBERT W.BRADORD FOUNDATION: "References Oxidology (ROS", CHULA VISTA, 1997
SILVIA VANNI MARCO ZATTTONIFABIO MODAGIORGIO GIACCONEFABRIZIO TAGLIAVINI ET AL.: "Hemoglobin mRNA changes in the frontal cortex of patients with neurodegenerative diseases", FRONT NEUROSCIENCES, 2018
STELLA GANGERKATHARINA SCHINDOWSKI, TAILORING FORMULATIONS FOR INTRANASAL NOSE-TO-BRAIN DELIVERY, 3 August 2018 (2018-08-03)
THERANOSTICS 2018, vol. 8, no. 15, 16 July 2018 (2018-07-16), pages 4129 - 4140
THERAPEUTIC DELIVERY, vol. 5, no. 6, 2014, pages 709 - 733, ISSN: 2041-5990
UTE PANZENBOECKZOLTAN BALAZSANDREA SOVICANDELKO HRZENJAKSANJA LEVAK-FRANKANDREA WINTERSPERGERERNST MALLEWOLFGANG SATTLER: "Institute of Medical Biochemistry and Medical Molecular Biology", 28 August 2002, UNIVERSITY GRAZ, JBC PAPERS IN PRESS, article "ABCA1 and Scavenger Receptor Class B, Type I, Are Modulators of Reverse Sterol Transport at an in Vitro Blood-Brain Barrier Constituted of Porcine Brain Capillary Endothelial Cells"

Also Published As

Publication number Publication date
IE20200056U1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
Khan et al. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease
Li et al. Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury
Guan et al. Tumor metabolism‐engineered composite nanoplatforms potentiate sonodynamic therapy via reshaping tumor microenvironment and facilitating electron–hole pairs’ separation
Kumar et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment
Zhou et al. Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy
Malouff et al. Carbon ion radiotherapy in the treatment of gliomas: a review
Lin et al. Human umbilical cord mesenchymal stem cells preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/macrophages
Zhao et al. MicroRNA-124: a key player in microglia-mediated inflammation in neurological diseases
Lee et al. Agouti related peptide secreted via human mesenchymal stem cells upregulates proteasome activity in an Alzheimer’s disease model
Eve et al. Reduction of microhemorrhages in the spinal cord of symptomatic ALS mice after intravenous human bone marrow stem cell transplantation accompanies repair of the blood-spinal cord barrier
Van Genugten et al. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
Alvarim et al. Therapeutics with SPION-labeled stem cells for the main diseases related to brain aging: a systematic review
Künkele et al. Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre
Noll et al. Neurocognition and health-related quality of life among patients with brain tumors
Jeon et al. Coulomb nanoradiator-mediated, site-specific thrombolytic proton treatment with a traversing pristine Bragg peak
Zhou et al. Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury
LU101272B1 (en) Route and engineering protocols for alzheimer&#39;s disease prevention, treatment and neuronal rebuilding
Bhatt et al. Current clinical trials in amyotrophic lateral sclerosis
Li et al. Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway
Wang et al. Chemical structure and shape enhance MR imaging-guided X-ray therapy following marginative delivery
Sulman et al. World Cancer Day 2021-perspectives in pediatric and adult neuro-oncology
Soffietti et al. Neurotoxicity from old and new radiation treatments for brain tumors
US20210000867A1 (en) New route and engineering protocols for alzheimers disease prevention, treatment and neuronal rebuilding
Hilton et al. Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice
Tracy et al. Intracerebral nanoparticle transport facilitated by alzheimer pathology and age

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20201228

NF Patent restored after lapse